LÄHDEKIRJALLISUUS

1. O'Neill DG, Scudder C, Faire JM, Church DB, McGreevy PD, Thomson PC ym. Epidemiology of hyperadrenocorticism among 210,824 dogs attending primary-care veterinary practices in the UK from 2009 to 2014. J Small Anim Pract. 2016;57:365-73.
2. Ling GV, Stabenfeldt GH, Comer KM, Gribble DH, Schechter RD. Canine hyperadrenocorticism: pretreatment clinical and laboratory evaluation of 117 cases. J Am Vet Med Assoc. 1979;174:1211-5.
3. Barker E, Campbell S, Tebb A, Neiger R, Herrtage M, Reid S ym. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism. J Vet intern Med. 2005;19:810-5.
4. Helm JR, McLauchlan G, Boden LA, Frowde PE, Collings AJ, Tebb AJ ym. A Comparison of Factors that Influence Survival in Dogs with Adrenal-Dependent Hyperadrenocorticism Treated with Mitotane or Trilostane. J Vet Intern Med. 2011;25:251-60.
5. Feldman EC. Distinguishing dogs with functioning adrenocortical tumors from dogs with pituitary-dependent hyperadrenocorticism. J Am Vet Med Assoc. 1983;183:195-200.
6. Jones TC, Hunt RD, King NW. Veterinary pathology. 6. painos. Baltimore: Williams & Wilkins; 1997.
7. Péres-Alenza D, Melià n C. Hyperadrenocorticism in dogs. Kirjassa Ettinger SJ, Feldman EC. Textbook of veterinary internal medicine : diseases of the dog and cat. 8. painos. St. Louis, Missouri: Elsevier Saunders; 2017, 1795-810.
8. Behrend EN. Canine Hyperadrenocorticism. Kirjassa Canine and feline endocrinology. 4. painos. Feldman EC, Nelson RW, Reusch CE, Scott-Moncrieff JCR, toim. St. Louis: W B Saunders; 2015, 377-451.
9. Machida T, Uchida E, Matsuda K, Hirayama K, Yoshii K, Takiguchi M ym. Aldosterone-, corticosterone-and cortisol-secreting adrenocortical carcinoma in a dog: case report. J Vet Med Sci. 2008;70:317-20.
10. Hoerauf A, Reusch C. Ultrasonographic Characteristics of Both Adrenal Glands in 15 Dogs with Functional Adrenocortical Tumors. J Am Anim Hosp Assoc. 1999;35:193-9.
11. Galac S, Kars VJ, Voorhout G, Mol JA, Kooistra HS. ACTH-independent hyperadrenocorticism due to food-dependent hypercortisolemia in a dog: A case report. Vet J. 2008;177:141-3.
12. Lacroix A, N' Diaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev. 2001;22:75-110.
13. Galac S, Kooistra H, Voorhout G, Van den Ingh T, Mol J, Van den Berg G ym. Hyperadrenocorticism in a dog due to ectopic secretion of adrenocorticotropic hormone. Domest Anim Endocrinol. 2005;28:338-48.
14. Churcher RK. Hepatic carcinoid, hypercortisolism and hypokalaemia in a dog. Aust Vet J. 1999;77:641-5.
15. Behrend EN, Kennis R. Atypical Cushing's syndrome in dogs: arguments for and against. Vet Clin N Am Small Anim Pract. 2010;40:285-96.
16. Behrend EN, Kemppainen RJ, Boozer AL, Whitley EM, Smith AN, Busch KA. Serum 17-a-hydroxyprogesterone and corticosterone concentrations in dogs with nonadrenal neoplasia and dogs with suspected hyperadrenocorticism. J Am Vet Med Assoc. 2005;227:1762-7.
17. Frank L, Henry GA, Whittemore JC, Enders B, Mawby DI, Rohrbach B. Serum cortisol concentrations in dogs with pituitary-dependent hyperadrenocorticism and atypical hyperadrenocorticism. J Vet Intern Med. 2015;29:193-9.
18. Huang HP, Yang HL, Liang SL, Lien YH, Chen KY. Iatrogenic hyperadrenocorticism in 28 dogs. J Am Anim Hosp Assoc. 1999;35:200-7.
19. Behrend EN, Kooistra HS, Nelson R, Reusch CE, Scott-Moncrieff JC. Diagnosis of spontaneous canine hyperadrenocorticism: 2012 ACVIM Consensus Statement (Small Animal). J Vet Intern Med. 2013;27:1292-304.
20. Zur G, White SD. Hyperadrenocorticism in 10 dogs with skin lesions as the only presenting clinical signs. J Am Anim Hosp Assoc. 2011;47:419-27.
21. van Vonderen IK, Kooistra HS, Rijnberk A. Influence of veterinary care on the urinary corticoid:creatinine ratio in dogs. J Vet Intern Med. 1998;12:431-5.
22. Mueller C, Sieber-Ruckstuhl N, Wenger M, Kaser-Hotz B, Reusch CE. Low-dose dexamethasone test with "inverse" results: a possible new pattern of cortisol response. Vet Rec. 2006;159:489-91.
23. Reusch CE, Feldman EC. Canine hyperadrenocorticism due to adrenocortical neoplasia: pretreatment evaluation of 41 dogs. J Vet Intern Med. 1991;5:3-10.
24. Kaplan AJ, Peterson ME, Kemppainen RJ. Effects of disease on the results of diagnostic tests for use in detecting hyperadrenocorticism in dogs. J Am Vet Med Assoc. 1995;207:445-51.
25. Müller PB, Wolfsheimer KJ, Taboada J, Hosgood G, Partington BP, Gaschen FP. Effects of long-term phenobarbital treatment on the thyroid and adrenal axis and adrenal function tests in dogs. J Vet Intern Med. 2000;14:157-64.
26. Ginel PJ, Sileo MT, Blanco B, Garfia B, Quintavalla F. Evaluation of serum concentrations of cortisol and sex hormones of adrenal gland origin after stimulation with two synthetic ACTH preparations in clinically normal dogs. Am J Vet Res. 2012;73:237-41.
27. Sieber-Ruckstuhl N, Burkhardt W, Hofer-Inteeworn N, Riond B, Rast I, Hofmann-Lehmann R ym. Cortisol response in healthy and diseased dogs after stimulation with a depot formulation of synthetic ACTH. J Vet Intern Med. 2015;29:1541-6.
28. Ristic JME, Ramsey IK, Heath E, Evans HJ, Herrtage ME. The Use of 17-hydroxyprogesterone in the diagnosis of canine hyperadrenocorticism. J Vet Intern Med. 2002;16:433-9.
29. Monroe WE, Panciera DL, Zimmerman KL. Concentrations of noncortisol adrenal steroids in response to acth in dogs with adrenal-dependent hyperadrenocorticism, pituitary-dependent hyperadrenocorticism, and nonadrenal illness. J Vet Intern Med. 2012;26:945-52.
30. Kemppainen RJ, Sartin JL. Evidence for episodic but not circadian activity in plasma concentrations of adrenocorticotrophin, cortisol and thyroxine in dogs. J Endocrinol. 1984;103:219-26.
31. European Society of Veterinary Endocrinology [kotisivu internetissä]. [päivitetty marraskuu 2018]. https:/ / esve.org/ esve/ eve-qas/ default.aspx.
32. Rodríguez Piñeiro M, Benchekroun G, Fornel-Thibaud D, Maurey-Guenec C, Garnier F, Rosenberg D. Accuracy of an adrenocorticotropic hormone (ACTH) immunoluminometric assay for differentiating ACTH-dependent from ACTH-independent hyperadrenocorticism in dogs. J Vet Intern Med. 2009;23:850-5.
33. Feldman EC, Nelson RW, Feldman MS. Use of low- and high-dose dexamethasone tests for distinguishing pituitary-dependent from adrenal tumor hyperadrenocorticism in dogs. J Am Vet Med Assoc. 1996;209:772-5.
34. Grooters AM, Biller DS, Theisen SK, Miyabayashi T. Ultrasonographic characteristics of the adrenal glands in dogs with pituitary-dependent hyperadrenocorticism: Comparison with normal dogs. J Vet Intern Med. 1996;10:110-5.
35. Pagani E, Tursi M, Lorenzi C, Tarducci A, Bruno B, Borgogno Mondino EC ym. Ultrasonographic features of adrenal gland lesions in dogs can aid in diagnosis. BMC Vet Res. 2016;12:267.
36. Kooistra HS, Voorhout G, Mol JA, Rijnberk A. Correlation between impairment of glucocorticoid feedback and the size of the pituitary gland in dogs with pituitary-dependent hyperadrenocorticism. J Endocrinol. 1997;152:387-94.
37. van der Vlugt-Meijer, Roselinda H, Meij BP, van den Ingh, Ted SGAM, Rijnberk A ym. Dynamic computed tomography of the pituitary gland in dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med. 2003;17:773-80.
38. Kim K, Han S, Jeon K, Kim H, Li Q, Ryu M ym. Clinical relationship between cholestatic disease and pituitary-dependent hyperadrenocorticism in dogs: a retrospective case series. J Vet Intern Med. 2017;31:335-42.
39. Lulich JP, Osborne CA, Thumchai R, Lekcharoensuk C, Ulrich LK, Koehler LA ym. Epidemiology of canine calcium oxalate uroliths. Identifying risk factors. Vet Clin North Am Small Anim Pract. 1999;29:113-22.
40. Miceli DD, Pignataro OP, Castillo V. Concurrent hyperadrenocorticism and diabetes mellitus in dogs. Res Vet Sci. 2017;115:425-31.
41. Rose L, Dunn M, Bedard C. Effect of canine hyperadrenocorticism on coagulation parameters. J Vet Intern Med. 2013;27:207-11.
42. Smets P, Lefebvre H, Meij B, Croubels S, Meyer E, Van de Maele I ym. Long-term follow-up of renal function in dogs after treatment for ACTH-dependent hyperadrenocorticism. J Vet Intern Med. 2012;26:565-74.
43. Soares FAC, Matheus JP, Carvalho GL, Neuwald EB, Pöppl ÁG, Valle SF ym. Cardiocirculatory, biochemical and hemostatic evaluation of dogs with hyperadrenocorticism at diagnosis and after treatment. Korean J Vet Res. 2016;56:161-6.
44. Nagata N, Kojima K, Yuki M. Comparison of survival times for dogs with pituitary-dependent hyperadrenocorticism in a primary-care hospital: treated with trilostane versus untreated. J Vet Intern Med. 2017;31:22-8.
45. Arenas C, Melián C, Pérez-Alenza M. Long-term survival of dogs with adrenal-dependent hyperadrenocorticism: A comparison between mitotane and twice daily trilostane treatment. J Vet Intern Med. 2014;28:473-80.
46. Ruckstuhl NS, Nett CS, Reusch CE. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Am J Vet Res. 2002;63:506-12.
47. Vaughan MA, Feldman EC, Hoar BR, Nelson RW. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism. J Am Vet Med Assoc. 2008;232:1321-8.
48. Ortega TM, Feldman EC, Nelson RW, Willits N, Cowgill LD. Systemic arterial blood pressure and urine protein/ creatinine ratio in dogs with hyperadrenocorticism. J Am Vet Med Assoc. 1996;209:1724-9.
49. Bonadio C, Feldman E, Cohen T, Kass P. Comparison of adrenocorticotropic hormone stimulation test results started 2 versus 4 hours after trilostane administration in dogs with naturally occurring hyperadrenocorticism. J Vet Intern Med. 2014;28:1239-43.

50. Arenas C, Melian C, Perez-Alenza M. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: Twice daily versus once daily. J Vet Intern Med. 2013;27:1478-85.

51. Feldman EC. Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism. J Am Vet Med Assoc. 2011;238:1441-51.

52. Boretti FS, Holzthum J, Reusch CE, Sieber-Ruckstuhl NS. Lack of association between clinical signs and laboratory parameters in dogs with hyperadrenocorticism before and during trilostane treatment. Schweiz Arch Tierheilkd. 2016;158:631-8.

53. Macfarlane L, Parkin T, Ramsey I. Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs. Vet Rec. 2016;179:597.

54. Reid L.E., Behrend E.N., Martin L.G., Kemppainen R.J., Ward C.R., Lurye J.C. ym. Effect of trilostane and mitotane on aldosterone secretory reserve in dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med. 2014;28:443-50.

55. Alenza DP, Arenas C, Lopez ML, Melian C. Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism. J Am Anim Hosp Assoc. 2006;42:269-76.

56. King J, Morton J. Incidence and risk factors for hypoadrenocorticism in dogs treated with trilostane. Vet J. 2017;230:24-9.

57. Chapman P, Kelly D, Archer J, Brockman D, Neiger R. Adrenal necrosis in a dog receiving trilostane for the treatment of hyperadrenocorticism. J Small Anim Pract. 2004;45:307-10.

58. Owen TJ, Martin LG, Chen AV. Transsphenoidal surgery for pituitary tumors and other sellar masses. Vet Clin North Am Small Anim Pract. 2018;48:129-51.

59. van Rijn SJ, Galac S, Tryfonidou MA, Hesselink JW, Penning LC, Kooistra HS ym. The influence of pituitary size on outcome after transsphenoidal hypophysectomy in a large cohort of dogs with pituitary-dependent hypercortisolism. J Vet Intern Med. 2016;30:989-95.

60. Meij B, Voorhout G, Rijnberk A. Progress in transsphenoidal hypophysectomy for treatment of pituitary-dependent hyperadrenocorticism in dogs and cats. Mol Cell Endocrinol. 2002;197:89-96.

61. Hanson JM, Teske E, Voorhout G, Galac S, Kooistra HS, Meij BP. Prognostic factors for outcome after transsphenoidal hypophysectomy in dogs with pituitary-dependent hyperadrenocorticism. J Neurosurg. 2007;107:830-40.

62. Vastenhout N, van Rijn S, Riemers F, Tryfonidou M, Meij B, Penning L. The mRNA expression of PTTG1 is a strong prognostic indicator for recurrence after hypophysectomy in dogs with corticotroph pituitary adenomas. Vet J. 2018;240:19-21.

63. de Fornel P, Delisle F, Devauchelle P, Rosenberg D. Effects of radiotherapy on pituitary corticotroph macrotumors in dogs: a retrospective study of 12 cases. Can Vet J. 2007;48:481-6.

64. Kent MS, Bommarito D, Feldman E, Theon AP. Survival, neurologic response, and prognostic factors in dogs with pituitary masses treated with radiation therapy and untreated dogs. J Vet Intern Med. 2007;21:1027-33.

65. Sawada H, Mori A, Lee P, Sugihara S, Oda H, Sako T. Pituitary size alteration and adverse effects of radiation therapy performed in 9 dogs with pituitary-dependent hypercortisolism. Res Vet Sci. 2018;118:19-26.

66. Barrera JS, Bernard F, Ehrhart E, Withrow SJ, Monnet E. Evaluation of risk factors for outcome associated with adrenal gland tumors with or without invasion of the caudal vena cava and treated via adrenalectomy in dogs: 86 cases (1993–2009). J Am Vet Med Assoc. 2013;242:1715-21.

67. Mayhew PD, Culp WT, Hunt GB, Steffey MA, Mayhew KN, Fuller M ym. Comparison of perioperative morbidity and mortality rates in dogs with noninvasive adrenocortical masses undergoing laparoscopic versus open adrenalectomy. J Am Vet Med Assoc. 2014;245:1028-35.

68. Sanders K, Kooistra HS, Galac S. Treating canine Cushing's syndrome: Current options and future prospects. Vet J. 2018;241:43-51.

69. Schwartz P, Kovak JR, Koprowski A, Ludwig LL, Monette S, Bergman PJ. Evaluation of prognostic factors in the surgical treatment of adrenal gland tumors in dogs: 41 cases (1999–2005). J Am Vet Med Assoc. 2008;232:77-84.

70. Mayhew PD, Culp WT, Balsa IM, Zwingenberger AL. Phrenicoabdominal venotomy for tumor thrombectomy in dogs with adrenal neoplasia and suspected vena caval invasion. Vet Surg. 2018;47:227-35.

71. Massari F, Nicoli S, Romanelli G, Buracco P, Zini E. Adrenalectomy in dogs with adrenal gland tumors: 52 cases (2002-2008). J Am Vet Med Assoc. 2011;239:216-21.

72. Kintzer PP, Peterson ME. Mitotane treatment of 32 dogs with cortisol-secreting adrenocortical neoplasms. J Am Vet Med Assoc. 1994;205:54-61.

73. Cai W, Djanegara T, Sinsheimer JE, Wotring LL, Counsell RE, Schteingart DE. Metabolic activation and binding of mitotane in adrenal cortex homogenates. J Pharm Sci. 1995;84:134-8.